Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders

The approved standard dose of pazopanib is 800 mg per day, but the appropriate dose of pazopanib to treat soft tissue sarcoma (STS) patients in real-world practice is controversial. Of 124 STS patients treated with pazopanib, we retrospectively analyzed the cases of STS patients who achieved progres...

Full description

Bibliographic Details
Main Authors: Kenji Nakano, Yuki Funauchi, Keiko Hayakawa, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Shunji Takahashi
Format: Article
Language:English
Published: MDPI AG 2019-01-01
Series:Journal of Clinical Medicine
Subjects:
soft tissue sarcoma
tyrosine kinase inhibitor
pazopanib
relative dose intensity
Online Access:http://www.mdpi.com/2077-0383/8/1/60

Internet

http://www.mdpi.com/2077-0383/8/1/60

Similar Items